M. Ansarin
Papers
1
Total Citations
2
H-Index
1
About
M. Ansarin is a leading surgical oncologist specializing in head and neck cancers, with a particular focus on minimally invasive trans-oral surgery (TOS) for oropharyngeal, supraglottic, and hypopharyngeal carcinomas. Their major contribution lies in pioneering comparative effectiveness research that rigorously evaluates TOS against radiotherapy for early-stage tumors, challenging traditional treatment paradigms. Ansarin’s landmark 2022 study, "706TiP Phase III study assessing the 'best of' radiotherapy compared to the 'best of' surgery," has garnered 2 citations and represents a critical step toward evidence-based personalization of care for patients with T1-T2, N0-N1 disease. This work directly addresses the long-standing debate between surgical and non-surgical approaches, aiming to optimize functional outcomes and survival. Ansarin’s research has significant implications for reducing treatment morbidity while maintaining oncologic efficacy, positioning them as a key figure in the evolution of head and neck cancer management. Their ongoing clinical trials continue to shape international guidelines, offering clearer pathways for clinicians and hope for patients facing these challenging diagnoses.
Research Focus
Key Achievements
Top Papers
- 1